Lang D F, Rosenfeld C S, Diamond H S, Shadduck R K, Zeigler Z R
Western Pennsylvania Cancer Inst., West Penn Hospital, Pittsburgh 15224.
Am J Hematol. 1992 May;40(1):66-8. doi: 10.1002/ajh.2830400115.
A trial of recombinant human granulocyte colony-stimulating factor (rhG-CSF) was attempted in a male with agranulocytosis, infection, and T-gamma lymphoproliferative disease (T-gamma-LPD). During five days of rhG-CSF (960 micrograms/day), the absolute neutrophil count (ANC) increased from 0.0 to 4.5 K/microliters. There were no changes in eosinophil or lymphocyte counts. In addition, there was no toxicity. Bone marrow cytotoxic/suppressor cells (CD57+/CD8+) were elevated (21.9%) before and decreased to 10.6% (normal less than 12%) following rhG-CSF. By contrast, there was no change in activated T cells (CD3+DR+) or T cell gene rearrangements. These findings suggest rhG-CSF can improve granulopoiesis in T-gamma-LPD, possibly by altering T-cell mediated marrow suppression.
对一名患有粒细胞缺乏症、感染和T-γ淋巴细胞增殖性疾病（T-γ-LPD）的男性患者尝试使用重组人粒细胞集落刺激因子（rhG-CSF）进行试验。在使用rhG-CSF（960微克/天）的五天期间，绝对中性粒细胞计数（ANC）从0.0升至4.5K/微升。嗜酸性粒细胞或淋巴细胞计数没有变化。此外，未出现毒性反应。骨髓细胞毒性/抑制细胞（CD57+/CD8+）在使用rhG-CSF前升高（21.9%），使用后降至10.6%（正常低于12%）。相比之下，活化T细胞（CD3+DR+）或T细胞基因重排没有变化。这些发现表明，rhG-CSF可能通过改变T细胞介导的骨髓抑制来改善T-γ-LPD中的粒细胞生成。
